Richard Clark

Designing novel conotoxins with therapeutic potential

Conotoxins, with their exquisite specificity and potency have recently created much excitement as drug leads for the treatment of chronic pain. For example, the conotoxin MVIIA (also known as Ziconotide or Prialt) has been approved for use in the U.S. and Europe for the treatment of pain and several other conotoxins have entered clinical trials. In addition, a number of conotoxins have played a critical role in dissecting the molecular mechanisms of ion channel and transporter functions in the nervous system.

There are projects available in the design of novel conotoxins that target specific receptors involved in pain.

Development of stable peptide-based drugs for the treatment of iron disorders

Hepcidin is the principal iron-regulatory hormone and the key mediator of iron overload (haemochromatosis) and anaemia of inflammation. This research project involves two development streams of peptide design, synthesis and structure/function analysis. The first stream will focus on the specific residues important for biological activity of hepcidin and the mutation of these residues to improve activity. The second stream will involve the development of stabilised analogues of native hepcidin. The two streams will coalesce during the final round of development to produce a series of novel cyclic hepcidin drug leads.